Tiger Brokers

BUZZ-Glaukos rises as FDA allows repeat use of glaucoma implant

Reuters
Jan 28
BUZZ-Glaukos rises as FDA allows repeat use of glaucoma implant

** Shares of medtech firm Glaukos GKOS.N rise 4% to $122.94 premarket

** Co says U.S. FDA now allows doctors to re-administer its "iDose TR" implant, which steadily releases glaucoma medicine to lower eye pressure

**  Glaucoma is a disease that damages the optic nerve, often due to high pressure inside the eye; the implant offers an option for patients who struggle with daily drops, per co

**  Co says updated labeling lets physicians remove the original implant and place a new one, with trials showing the approach was safe over a year

** GKOS says the device is not advised for patients with certain corneal issues or infections

** Shares down ~25% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10